- 询价
- WYTSCI
- 进口
- WT-AY-B11165
- 2025年07月16日
2 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20°C
- 保质期：
咨询
- 英文名：
Maraviroc
- 库存：
1000+
- 供应商：
上海维亦特生物
- CAS号：
376348-65-1
纯度：>98% by HPLC；NMR (Conforms)
分子式：C29H41F2N5O
分子量：513.68
溶剂：DMSO (>25 mg/ml)
性状：White solid
存储：-20°C
Activity (short version)：CCR5 antagonist
Function / Pharmacology：Potent and selective CCR5 antagonist with potent anti-HIV activity. It prevents HIV-1 gp120 binding to CCR5 preventing cell-cell fusion. Maraviroc inhibited MIP-1a (IC50 = 3.3 nM), MIP-1b (IC50 = 7.2 nM), and RANTES (IC50 = 5.2 nM) binding to CCR5-expressing HEK-293.1 Clinically useful antiretroviral drug. Many cancer cells express CCR5: Maraviroc blocked metastasis of basal breast2 and pancreatic cancer3 cells, induced cytotoxic and apoptotic effects in colorectal cancer cells4, reduced metastatic tumor growth in lungs5, and suppresses growth in acute ALL cells6. CCR5 inhibition with maraviroc induced macrophage repolarization with anti-tumoral effects.7
分子式：C29H41F2N5O
分子量：513.68
溶剂：DMSO (>25 mg/ml)
性状：White solid
存储：-20°C
Activity (short version)：CCR5 antagonist
Function / Pharmacology：Potent and selective CCR5 antagonist with potent anti-HIV activity. It prevents HIV-1 gp120 binding to CCR5 preventing cell-cell fusion. Maraviroc inhibited MIP-1a (IC50 = 3.3 nM), MIP-1b (IC50 = 7.2 nM), and RANTES (IC50 = 5.2 nM) binding to CCR5-expressing HEK-293.1 Clinically useful antiretroviral drug. Many cancer cells express CCR5: Maraviroc blocked metastasis of basal breast2 and pancreatic cancer3 cells, induced cytotoxic and apoptotic effects in colorectal cancer cells4, reduced metastatic tumor growth in lungs5, and suppresses growth in acute ALL cells6. CCR5 inhibition with maraviroc induced macrophage repolarization with anti-tumoral effects.7
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
376348-65-1
相关实验
文献速递｜Science 子刊 ：少突胶质前体细胞调控免疫反应及多发性硬化症早期脱髓鞘新机制
下，OPC 的 Wnt 信号过度激活，分泌趋化因子 CCL4，招募外周 CD4⁺ T 细胞浸润中枢神经系统，并与高 Wnt 信号通路的 OPC 协同作用，诱导外周巨噬细胞转化为细胞毒性巨噬细胞亚群，导致病程早期的快速脱髓鞘反应。更关键的是，团队利用临床已获批的 CCR5 拮抗剂马拉韦罗（Maraviroc, MVC）成功阻断该病理性级联反应，为 MS 早期干预提供了全新策略。 研究团队通过构建 OPC 特异性 Wnt 通路激活小鼠（PdgfraCreER;Apcfl/fl），发现
Overview of Receptor Allosterism
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith‐Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., and Perros, M. 2005. Maraviroc (UK‐427,857
技术资料暂无技术资料 索取技术资料
文献支持
Maraviroc
询价
